SCHEMBL2179639

SCHEMBL2179639

O=C(Nc1ccc(-c2ccc3c(c2)C(=O)N(C2CCCC2C(=O)O)C3)cc1)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 4/20 0.53
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
P2RY14 Q15391 1/20 0.43
MCHR1 Q99705 3/20 0.42
POLB P06746 1/20 0.41
DPP4 P27487 1/20 0.41
ITGB3 P05106 2/20 0.41
ITGA2B P08514 2/20 0.41
ITGA2 P17301 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2356973 1.00 DGAT1 (0.53) DGAT1MEN1KMT2ARXFP1P2RY14
SCHEMBL13718868 0.91 DGAT1 (0.46) DGAT1MCHR1RAB9A
SCHEMBL2228439 0.91 DGAT1 (0.46) DGAT1MCHR1RAB9A
SCHEMBL2179473 0.89 DGAT1 (0.43) DGAT1MCHR1POLBRAB9A
SCHEMBL2178972 0.89 DGAT1 (0.43) DGAT1MCHR1POLBRAB9A
SCHEMBL13718607 0.87 DGAT1 (0.46) DGAT1MEN1KMT2ARXFP1P2RY14
SCHEMBL15764363 0.85 MEN1 (0.41) DGAT1MEN1KMT2ARXFP1P2RY14
SCHEMBL2179791 0.85 JAK2 (0.44) DGAT1MEN1KMT2ARXFP1P2RY14
SCHEMBL2179789 0.85 JAK2 (0.44) DGAT1MEN1KMT2ARXFP1P2RY14
SCHEMBL2180267 0.80 MEN1 (0.42) DGAT1MEN1KMT2ARXFP1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT DGAT1 1/4885MEN1 3071/4885KMT2A 1705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.